Experience of using anti-CD 20 therapies in multiple sclerosis patients in Kenya
Nyambane Eunice, Tejal Patel, Jacqueline Mavuti, Juzar Hooker, Dilraj Sokhi · 2026
Read Experience of using anti-CD 20 therapies in multiple sclerosis patients in Kenya by Nyambane Eunice, Tejal Patel, Jacqueline Mavuti, Juzar Hooker, Dilraj Sokhi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12883392.txt.
Description
Nyambane Eunice and co-authors report in a study published in 2025 on the use of two antibody drugs for multiple sclerosis in Kenya. The drugs, ocrelizumab and rituximab, drain a class of immune cells and are given by drip every six months. Data on their use in Kenya were scarce, so the team read records at a Nairobi hospital.
Sixty-seven patients treated between 2016 and 2025 were reviewed, most with the relapsing form of the disease. After one year, patients with a relapse fell from forty-eight to seven. Scans stayed stable in forty patients, and no drip reactions or life-threatening infections were reported. The drugs look safe and effective in this setting.
Catalog record
| CREATOR | Nyambane Eunice, Tejal Patel, Jacqueline Mavuti, Juzar Hooker, Dilraj Sokhi |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 17 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |